New sublingual delivery system designed to provide more rapid relief from nausea caused by cancer medicinesOndansetron, ...

CHATHAM, N.J., Jan. 30, 2026 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) ("Tonix" or the "Company"), a fully integrated, commercial biotechnology company, presented data on ...

New sublingual delivery system designed to enhance bioavailability and speed of onset for major depressive and ...

Microsize brings over thirty years of expertise in specialized particle size engineering for the pharmaceutical ...

Buprenorphine sublingual tablet is prescribed to treat opioid use disorder in two phases: an induction phase to manage initial withdrawal symptoms and a maintenance phase for long-term treatment. You ...

CHATHAM, N.J., Aug. 15, 2025 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (TNXP), a fully-integrated biotechnology company, today announced that the U.S. Food and Drug Administration (FDA) ...

More than 15 years ago, Yale's Gail D'Onofrio started studying the effectiveness of sublingual (under-the-tongue) buprenorphine for treatment of opioid use disorder (OUD) in the emergency department.

The United States Food and Drug Administration recently approved Tonmya TM (cyclobenzaprine hydrochloride sublingual tablets) ...

Zolpidem tartrate 1.75mg, 3.5mg. Use lowest effective dose. Effects delayed if taken with or after a meal. Place 1 tab under the tongue and allow to disintegrate completely before swallowing. Take ...

TONMYA demonstrated significant reduction in fibromyalgia pain compared with placebo in the Phase 3 RESILIENT study Unique sublingual formulation designed for bedtime dosing bypasses first-pass ...

Detailed price information for Tonix Pharm Holdings (TNXP-Q) from The Globe and Mail including charting and trades.